TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 96062
Drug: Neutron-telecobalt therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutron-telecobalt therapy
Study: 96062
Drug: Telecobalt therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telecobalt therapy
Study: 19496838
Drug: Topical gluco-oligosaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gluco-oligosaccharide and collagen tripeptide F
Study: 14505916
Drug: Botulinum F
Normalized name: botulinum neurotoxin F immune FAB2
DrugBank: Equine Botulinum Neurotoxin F Immune FAB2 (DB13901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum F toxoid vaccine (Bot F) administered 1-3 times
Study: 14505916
Drug: Botulinum F
Normalized name: botulinum neurotoxin F immune FAB2
DrugBank: Equine Botulinum Neurotoxin F Immune FAB2 (DB13901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum F toxoid vaccine (Bot F) administered 3 times over 28-42 days
Study: 14505916
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of Botulinum F toxoid vaccine (Bot F) administered at 1 year
Study: 14505916
Drug: Licensed, alum-adsorbed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed, alum-adsorbed hepatitis B vaccine (Engerix-B)
Study: 8632929
Drug: Nebulized budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nebulized budesonide (4 mL, 2 mg)
Study: 8632929
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 mL of 0.9% saline solution)
Study: 1483494
Drug: +/- Nicardipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: +/- Nicardipine 50 mg b.d.
Study: 1483494
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release nifedipine 20 mg b.d.
Study: 31508899
Drug: Imipenem/relebactam 500/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem/relebactam 500/250 mg administered as a 30-minute intravenous infusion four times daily.
Study: 29215518
Drug: Low-Molecular-Weight Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-Molecular-Weight Heparin + Aspirin
Study: 24657003
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy plus trastuzumab
Study: 24657003
Drug: Pathological complete
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pathological complete response with chemotherapy alone
Study: 20814327
Drug: Persistent medication
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Persistent medication refusal (114 patients, 18.8%)
Study: 16087788
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg per day administered on awakening
Study: 16087788
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg per day administered at bedtime
Study: 16087788
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg per day administered at bedtime in non-dipper patients
Study: 16087788
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg per day administered at bedtime in dipper patients
Study: 10383561
Drug: Microencapsulated aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microencapsulated aspirin 162.5 mg
Study: 10383561
Drug: Aspirin EC
Normalized name: Aspirin EC
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin EC 150 mg
Study: 10383561
Drug: Aspirin EC
Normalized name: Aspirin EC
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin EC 75 mg
Study: 18958842
Drug: rosiglitazone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone (8 mg daily)
Study: 10860192
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (nisoldipine or enalapril)
Study: 10860192
Drug: Moderate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate therapy (nisoldipine or enalapril)
Study: 9217378
Drug: Methylprednisolone 500
Normalized name: methylprednisolone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 500 mg administered 2 hours before operation (group S)
Study: 9217378
Drug: No pre-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pre-treatment (group C)
Study: 3403101
Drug: L-carnitine (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (1-g doses twice daily for 45 days)
Study: 29402258
Drug: Home-based play-assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based play-assisted stimulation for 1 hour during weekly home visits over 6 months
Study: 27305924
Drug: 240 J
Normalized name: Vitamin J
DrugBank: Choline (DB00122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 240 J dose of near-infrared (NIR) light therapy
Study: 31551349
Drug: Sham dose
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham dose
Study: 23837606
Drug: Goal-directed hemodynamic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed hemodynamic treatment (GDHT)
Study: 23837606
Drug: Routine fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine fluid treatment
Study: 20946674
Drug: Tutoring by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tutoring by a combination of content experts for 11 sessions and process experts for 10 sessions (n = 3)
Study: 18257904
Drug: Non-ribavirin treatment
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Non-ribavirin treatment (Control B)
Study: 16414295
Drug: Alfentanil (25ng/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (25ng/ml and 75ng/ml)
Study: 16414295
Drug: Morphine (0.14mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (0.14mg/kg and 0.28mg/kg)
Study: 9300118
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide during active treatment periods in children with asthma (aged 12-16 years)
Study: 8337162
Drug: Intravenous lorazepam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lorazepam (Ativan)
Study: 8337162
Drug: Intravenous prochlorperazine
Normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prochlorperazine (Compazine)
Study: 3095557
Drug: Enteral feeding
Normalized name: enteral feeding dispenser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral feeding via needle catheter jejunostomy (N.C.J.) with an elemental diet (Vivonex HN) starting at 18 hours and advanced to 3,000 ml/day (3,000 kcal, 20 gm N2) within 72 hours.
Study: 30232858
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment (30 min, once daily, 6 times a week for 30 days)
Study: 30232858
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride (5 mg/night for 30 days)
Study: 27532525
Drug: Fluconazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (two doses of 300mg given 1 week apart)
Study: 27532525
Drug: Fluconazole (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (two doses of 300mg given 1 week apart) + Ketoconazole shampoo (one application)
Study: 24418570
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) applied bilaterally to the quadriceps muscles, n = 11, 8 weeks, 5 days/week, twice/day, 45 min/session
Study: 18397984
Drug: Berberine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (1.0 g daily)
Study: 12005274
Drug: Frovatriptan (0.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan (0.5, 1, 2.5, or 5 mg)
Study: 12005274
Drug: Frovatriptan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frovatriptan (all doses)
Study: 9347681
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (1800 mg of eicosapentanoic acid [EPA] + 1200 mg of docosahexanoic acid) with garlic powder (1200 mg) capsules daily for 1 month
Study: 8516490
Drug: Nitrendipine (calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (calcium antagonist)
Study: 29064409
Drug: Eicosapentaenoic acid/Docosahexaenoic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) diet (10:1 plus supplement)
Study: 29064409
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (2:1 + S)
Study: 26216528
Drug: Endogenous molecules
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Endogenous molecules (metabolites such as tryptophan, alanine, arachidonic acid, 2-hydroxybutyric acid, cholesterol, and isoleucine)
Study: 21502571
Drug: Atopaxar 50
Normalized name: Atopaxar
DrugBank: Atopaxar (DB12046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopaxar 50 mg daily
Study: 21502571
Drug: Atopaxar 100
Normalized name: Atopaxar
DrugBank: Atopaxar (DB12046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopaxar 100 mg daily
Study: 21502571
Drug: Atopaxar 200
Normalized name: Atopaxar
DrugBank: Atopaxar (DB12046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopaxar 200 mg daily
Study: 21502571
Drug: Atopaxar (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atopaxar (higher doses)
Study: 19662793
Drug: 5% glucose
Normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% glucose solution (1000 mL) one day before surgery
Study: 19662793
Drug: Postoperative non‐glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative non‐glucose crystalloid solutions
Study: 19662793
Drug: Postoperative use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative use of insulin
Study: 19662793
Drug: Postoperative replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative replacement with cristalloids and insulin
Study: 16445447
Drug: Intracameral mydriatics
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intracameral mydriatics (ICM) solution
Study: 15538125
Drug: Augmentation strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation strategy with risperidone
Study: 8176922
Drug: Three courses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of cisplatinum containing combination chemotherapy
Study: 8176922
Drug: Less than
Normalized name: IgA less than or equal to 50 mcg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less than three courses of chemotherapy
Study: 27439370
Drug: Abediterol 5
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 5 μg
Study: 27439370
Drug: Abediterol 10
Normalized name: Abediterol
DrugBank: Abediterol (DB12100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abediterol 10 μg
Study: 22078184
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of MPA 25 mg + E(2)-Cyp 5 mg
Study: 22078184
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of MPA 25 mg + E(2)-Cyp 5 mg
Study: 22078184
Drug: Both SC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both SC and IM administration
Study: 18077124
Drug: Methadone maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone maintenance therapy throughout pregnancy
Study: 16365743
Drug: Cisplatin 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 12.5 mg/m(2) plus radiation 36 Gy
Study: 16365743
Drug: Taxol 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxol 40 mg/m(2)/carboplatin AUC 1.5 plus radiation 40 Gy
Study: 11105938
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg per hour)
Study: 8815669
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (catheters thoroughly washed before microwave treatment)
Study: 2533878
Drug: 4% erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% erythromycin and zinc combination (Zineryt)
Study: 335571
Drug: dl-alpha-tocopheryl nicotinate
Normalized name: DL-alpha tocopheryl acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: dl-alpha-tocopheryl nicotinate (600 mg, 6 capsules a day)
Study: 30040242
Drug: Nonanimal chondroitin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonanimal chondroitin sulfate (800 mg tablet)
Study: 25141240
Drug: Intact ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact ER OC/APAP 30/1300 mg
Study: 25141240
Drug: Intact IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact IR OC/APAP 30/1300 mg
Study: 25141240
Drug: Intact ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intact ER OC/APAP 15/650 mg
Study: 25141240
Drug: Crushed ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crushed ER OC/APAP 30/1300 mg
Study: 20659607
Drug: Dexmedetomidine 1
Normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1 microg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Study: 20659607
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg.kg(‐1).h(‐1) followed by a reduction by half in the rate of infusion
Study: 17987388
Drug: Self-administered with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered with telephone support (SA)
Study: 17987388
Drug: Group-administered (PA)
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-administered (PA)
Study: 1760713
Drug: MCT/LCT solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT/LCT solution
Study: 1760713
Drug: LCT solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT solution
Study: 1760713
Drug: LCT-containing solution
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCT-containing solution
Study: 1760713
Drug: MCT-containing solutions
Normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCT-containing solutions
Study: 6291361
Drug: Captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CPT) 6.25 mg
Study: 6291361
Drug: Captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CPT) 12.5 mg
Study: 6291361
Drug: Captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CPT) 12.5 to 50 mg every 8 hours long-term
Study: 6291361
Drug: Captopril (CPT)
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Captopril (CPT) 25 mg
Study: 22898037
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus bevacizumab (15 mg/kg on day 1 given intravenously every 21 days until disease progression)
Study: 21471258
Drug: Bupivacaine group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine group (20 mL bupivacaine 0.25% and 0.5 mL adrenaline 1/200,000 each side)
Study: 21471258
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20.5 mL normal saline each side)
Study: 11158752
Drug: Gemifloxacin 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 160 mg once daily for 7 days
Study: 11158752
Drug: Gemifloxacin 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 480 mg once daily for 7 days
Study: 11158752
Drug: Gemifloxacin 640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin 640 mg once daily for 7 days
Study: 11158752
Drug: Gemifloxacin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemifloxacin (all doses)
Study: 1335650
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (SmithKline Beecham Biologicals)
Study: 27109264
Drug: Taurine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taurine (6 g)
Study: 27109264
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g dextrose)
Study: 15943592
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (30 microg/m(2) body surface area/24 h)
Study: 12861239
Drug: Abbreviated Progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abbreviated Progressive Muscle Relaxation Therapy (APRT)
Study: 10774661
Drug: SB MMR
Normalized name: MMR
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB MMR vaccine
Study: 10774661
Drug: Merck MMR
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Merck MMR vaccine
Study: 8683240
Drug: Tamoxifen (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (160 mg orally daily for 7 days before chemotherapy and 40 mg orally daily throughout the treatment cycle)
Study: 8683240
Drug: Placebo (given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (given with the same chemotherapy regimen)
Study: 1929686
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 0.3 mg
Study: 1929686
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 0.625 mg
Study: 1929686
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg
Study: 3881155
Drug: Incision, curettage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incision, curettage and primary suture without parenteral antibiotics (64 cases)
Study: 3881155
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment with incision, drainage and dressings (73 cases)
Study: 29981863
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (chronic DOAC administration)
Study: 22145978
Drug: Conventional SLA
Normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional SLA implants
Study: 22145978
Drug: Chemically modified
Normalized name: Chemically modified recombinant sulfamidase
DrugBank: SOBI-003 (DB15451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemically modified SLA (modSLA) implants
Study: 12707465
Drug: Continuous therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous therapy (3-5 mg/kg/day initially, then 0.5-3 mg/kg/day after remission)
Study: 12707465
Drug: Intermittent therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent therapy (3-5 mg/kg/day initially, then tapered off after remission)
Study: 10784478
Drug: Divalproex treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex treatment for 6 weeks
Study: 10784478
Drug: Divalproex treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divalproex treatment for 6 weeks (in subjects who completed both phases)
Study: 8982753
Drug: Oestradiol patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol patch (100 micrograms/day for 6 weeks)
Study: 8982753
Drug: Oestradiol patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestradiol patch
Study: 6150945
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg propranolol
Study: 30203757
Drug: Nasal continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal continuous positive airway pressure plus high-dose ambroxol
Study: 26263283
Drug: 0.1 mg/hour
Normalized name: nitroglycerin 0.1 mg/hour TRANSDERM PATCH, TRANSDERMAL 24 HOURS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/hour nitroglycerin patch applied daily, escalating to 0.2, 0.4, or 0.6 mg/hour as tolerated
Study: 26263283
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of nitroglycerin
Study: 7600653
Drug: Carvedilol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (up to 25 mg BID)
Study: 2194642
Drug: Metoclopramide (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) without Dexamethasone
Study: 2194642
Drug: Metoclopramide (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) with Dexamethasone (0.5 mg/kg)
Study: 221114
Drug: Cyclic alternating
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic alternating combination chemotherapy with high‐dose cyclophosphamide, methotrexate, and CCNU (CMC) followed by vincristine, adriamycin, and procarbazine (VAP) for 6 weeks each.
Study: 221114
Drug: Addition of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addition of VAP after CMC treatment.
Study: 30278430
Drug: Resveratrol 100
Normalized name: resveratrol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 100 mg/d
Study: 30278430
Drug: Placebo (sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sucrose 0.5 g/d)
Study: 23328268
Drug: Clopidogrel napadisilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel napadisilate plus aspirin
Study: 23328268
Drug: Clopidogrel bisulfate
Normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel bisulfate plus aspirin